Xenon Pharmaceuticals (XENE) Stock Analysis & AI Equity Report
Xenon Pharmaceuticals (XENE) overview
Xenon Pharmaceuticals (XENE) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 7.5m and operating profit of USD -373m; the year-end share price was 44.82 USD and market capitalisation was USD 3,586m. Xenon Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Xenon Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Xenon Pharmaceuticals
Xenon Pharmaceuticals is a neuroscience biopharmaceutical company developing treatments for neurological and psychiatric disorders. Its lead candidate azetukalner, a Kv7 potassium channel opener, has an NDA submitted to the FDA for focal seizures and is in Phase 3 studies for epilepsy. The company completed enrollment in a Phase 3 major depressive disorder study and continues to develop earlier-stage ion-channel programs for pain and other conditions.
Generate the Xenon Pharmaceuticals report
Xenon Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Xenon Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Xenon Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.